This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Mykytsey, A. Articles by Kehoe, R. F. Search for Related Content PubMed PubMed Citation Articles by Mykytsey, A. Articles by Kehoe, R. F. Social Bookmarking                         What's this?

Observations on the Safety and Effectiveness of Dofetilide in Patients With Paroxysmal Atrial Fibrillation and Normal Left Ventricular Function

Advocate Illinois Masonic Medical Center, Chicago, Illinois

Jerry L. Bauman, PharmD

University of Illinois at Chicago

Mansour Razminia, MD

Advocate Illinois Masonic Medical Center, Chicago, Illinois

Terry Zheutlin, MD

Advocate Illinois Masonic Medical Center, Chicago, Illinois

Ted Wang, MD

Advocate Illinois Masonic Medical Center, Chicago, Illinois

Mohammad Saleem, MD

Advocate Illinois Masonic Medical Center, Chicago, Illinois

Sergio Leal, MD

Advocate Illinois Masonic Medical Center, Chicago, Illinois

Richard F. Kehoe, MD

Advocate Illinois Masonic Medical Center, Chicago, Illinois, Richard.Kehoe-MD{at}advocatehealth.com

Dofetilide is currently recommended as second-tier therapy to maintain sinus rhythm in patients with paroxysmal atrial fibrillation (PAF) and normal left ventricular function, yet limited data support this recommendation. We examined the safety and efficacy of dofetilide in this setting through a retrospective chart review. We evaluated patients who had symptomatic PAF, normal left ventricular function, and no significant valvular disease. The end points were complete suppression of symptomatic PAF and subjective symptomatic improvement with dofetilide treatment. Over a 3-year period, 34 patients who had failed previous antiarrhythmic therapy were included. Of these, 3 discontinued dofetilide treatment before discharge. Of the remaining 31 who continued treatment after discharge, it was eventually discontinued in 13. At 12 months, symptomatic improvement was observed in 18 of 31 patients, 6 of whom remained asymptomatic. Treatment with dofetilide in this study was successful in less than 1 in 5 patients. Despite careful precautions, serious proarrhythmias, the major limiting side effect of dofetilide, still occurred during long-term follow-up.

Key Words: paroxysmal atrial fibrillation • dofetilide • proarrhythmia • symptomatic improvement

Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 12, No. 1, 36-43 (2007)
DOI: 10.1177/1074248407299272


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?